Shareholders Foundation, Inc.

NYSEMKT:IMUC Investor Alert: Lawsuit Alleges Misleading Statements by ImmunoCellular Therapeutics Ltd

A lawsuit was filed on behalf of investors in ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares over alleged securities laws violations. Deadline: June 30, 2017. NYSEMKT:IMUC investors should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 05/24/2017 -- An investor in NYSEMKT:IMUC shares filed a lawsuit against ImmunoCellular Therapeutics over alleged Securities Laws violations.

Investors who purchased shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff claims that the defendants developed a scheme to manipulate and artificially inflate the stock price of ImmunoCellular Therapeutics Ltd and that by virtue of this scheme, the market was conditioned to believe that ImmunoCellular's clinical studies for ICT-107 were going well as the placement of these fraudulent media reports were often timed to coincide with ImmunoCellular's announcements of ICT-107, so to have maximum impact upon ImmunoCellular's share price.

The plaintiff claims that unbeknownst to the market, beginning in September 2011, ImmunoCellular Therapeutics Ltd hired Lidingo Holdings, LLC, a stock promotional firm to pump up the value of ImmunoCellular Therapeutics Ltd stock and that this endeavor included a campaign of planting phony analyst reports and news articles that fawned over ImmunoCellular Therapeutics Ltd, and that in many cases, these phony media reports were written under aliases, and failed to reveal that ImmunoCellular had complete editorial control over their work.

Those who purchased shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com